Peter Reynolds

The life and times of Peter Reynolds

Posts Tagged ‘peter reynolds

Probably The Biggest Breakthrough Yet For Medicinal Cannabis In The UK.

leave a comment »

Peter Reynolds, President, CLEAR Cannabis Law Reform

Since the beginning of 2017, Peter Reynolds and Professor Mike Barnes of CLEAR Cannabis Law Reform have been working on a project that is about to come to fruition.  The Council of the Royal College of General Practitioners (RCGP) meets tomorrow, 22nd September 2017, to consider our proposal to issue guidelines to doctors on the use of medicinal cannabis.

Professor Mike Barnes, Scientific & Medical Advisor, CLEAR Cannabis Law Reform

As ever, the UK’s stubborn, anti-evidence government remains intransigent on permitting legal access to cannabis, even for medicinal use.  This despite an overwhelming tide of reform across the world and the reality that perhaps one million people in the UK are criminalised and persecuted for using a medicine that has been known to be safe and effective for many centuries, facts which modern science now proves beyond doubt.

However irresponsible and pig-headed government ministers may be, doctors have a responsibility to their patients, an ethical duty that transcends the grubby and corrupt politics that ministers subscribe to. Professor Nigel Mathers, Honorary Secretary of the RCGP with responsibility for its governance, has championed CLEAR’s proposal.  He recognises that while doctors cannot be advising their patients to use an illegal drug, the reality is many people already are.

Professor Nigel Mathers, Honorary Secretary, Royal College of GPs

So this is not just another report or a conference.  This is practical action at the point of delivery of healthcare.  If the proposal is approved by the RCGP Council, the guidelines will be drafted by Professor Mike Barnes, assisted by Peter Reynolds, with additional input from the MS Society and Newcastle University.

In due course, probably by the end of the year, a booklet will be available for download by all GPs from the RCGP website.  It will set out balanced and reasonable advice on the appropriate use of cannabis for specific medical indications. The guidelines will also cover harm reduction advice and provide a basic grounding in the scientific evidence and the endocannabinoid system.

If our government refuses to take such sensible steps to improve healthcare and protect patients, then we, campaigners and medical professionals, must do it for them.

 

Advertisements

VIDEO. Peter Reynolds Speaks At The Oxford Union On Drugs Policy.

leave a comment »

‘This House Would Say No To Drugs’, The Oxford Union, 16th February 2017.

with 5 comments

pjr-deangelo-crop

Peter Reynolds, Stephen DeAngelo

On Thursday, 16th February 2017, the Oxford Union held a debate on the motion ‘This House Would Say No To Drugs’.

thwsntd-graphicI was honoured to be invited to speak against the motion in the august company of Paul Hayes and Stephen DeAngelo. Speaking for the motion were Andrew Ng, Assistant Commissioner Patricia Gallan and Shaun Attwood.

We successfully defeated the motion by approximately 120 votes to 90.  A video of the debate will be released shortly.  I reproduce my speech below.

“Reefer makes darkies think they’re as good as white men.”

These are the words of Harry Anslinger, who in 1930 was appointed the first ever commissioner of the US Federal Bureau of Narcotics. 

And this is the exactly same standard of argument and evidence that we have in favour of drug prohibition today.

Anslinger went on to start the war on drugs 40 years before Richard Nixon invented the term.  His anti-cannabis crusade was based on racism, the suggestion that it caused madness, violence and depravity – yes, the same scare stories, myths and deceit that we still see published every day in the pages of the Daily Mail and the Daily Telegraph.  Indeed, exactly the same nonsense which every home secretary continues to trot out and on which our present prime minister bases UK drugs policy.

Don’t be in any doubt about it, the Home Office, under successive governments, has been engaged in the systematic deception of the British public.  It misleads, misinforms and repeatedly publishes bare faced lies about drugs and drugs policy and subverts every effort towards reform advocated by more enlightened politicians. 

In 2013, according to Norman Baker and Nick Clegg, Theresa May tried to falsify the international comparators report which showed that across the world harsh penalties make no difference to the level of drug use.  The facts simply don’t fit with her ideology.

And this idiocy pervades our society.  It is reflected in this motion which I oppose.  The premise of ‘This House Would Say No to Drugs’ is false from the very start.  It’s preposterous! We all say yes to drugs, every day, inevitably, in cocktails of medicines and recreational stimulants, in food, drink, in endogenous highs released through exercise and emotions, repeatedly, regularly, all of us, without exception, do drugs.

That our governments have seen fit to draw arbitrary lines as to which drugs are acceptable and which are not, which drugs that we can celebrate and which we will be locked up for, has nothing to do with evidence, science and, least of all, absolutely nothing to do with how harmful or dangerous they are. They are based on prejudice and thinking in 2017 that has advanced no further than Harry Anslinger in 1930. 

Sometimes these prejudices have strange echoes in the past. Coffee was banned in Mecca in 1511, as it was believed to stimulate radical thinking – the governor thought it might unite his opposition. What does that remind you of?

Often these lines are not arbitrary, they are based on vested interests. In 1777, Frederick the Great of Prussia also tried to ban coffee. He argued it interfered with the country’s beer consumption.  Before the first International Opium Convention in 1925 Egyptian cotton farmers successfully lobbied for cannabis to be banned as they feared the superior fibre crop of hemp.  Back to Harry Anslinger and he was in league with the timber barons who greatly feared the far better option of using hemp to make paper and the fledging oil industry which had just invented nylon, a synthetic alternative to the job that hemp fibre had done for thousands of years.  When Henry Ford invented the Model T he designed it to run on ethanol produced from hemp. He planted hemp on his own land for the purpose.  It’s no conspiracy theory to argue that the entire oil industry in predicated on the prohibition of cannabis, it’s just good, solid evidence.

Today, in the UK, prohibition of much safer substances like cannabis and MDMA is enforced to preserve the monopoly of legal recreational drugs that belongs to the alcohol industry – a drug that is at least a dangerous as heroin and causes far more misery and death in our society.  It’s no surprise when the UK alcohol industry spends £800 million every year on advertising that the media which enjoys that income supports the alcohol monopoly.

As if we didn’t have the clearest possible lesson from the prohibition of alcohol which gave birth to organised crime and demonstrated beyond any doubt that prohibition never works, it just makes the problem worse.  

The UK is more backwards, more disgraced, more shamed by a drugs policy that causes far more harm than it prevents, than almost any other first world country.

Prohibition is a fundamentally immoral policy.  If you remember one thing that I say today, please make it this. It sets law enforcement against the communities it is supposed to protect.  Being a police office is a noble and honourable calling.  Every society needs policing but drugs policy has perverted this profession.  The demand for what are deemed illicit drugs comes from society but instead of protecting us from danger, police action increases the dangers we are subject to.   The harder the police clamp down, the more the price of drugs rises, the more unscrupulous and violent the unregulated criminal trade becomes and the more contaminated, more concentrated and more dangerous are the drugs themselves.

In Amsterdam, there is no problem with Spice, the synthetic cannabinoid that is ravaging our streets and British prisons at present.  In sane, civilised society like California, Colorado or Washington, where adults can access safe, properly regulated cannabis, there is no Spice problem like we have in the UK. This disgusting, horrible product is the direct responsibility of the politicians who continue to pursue our ignorant anti-cannabis policy.  It is just one example of the great, immoral evil that prohibition causes.  And I ask you, if this crazy policy of prohibition cannot be enforced in prisons, then how do we expect to enforce it in wider society?

It is prohibition and drugs policy based on prejudice that destroys police and community relations.  It is current policy that means 70% of all acquisitive crime is caused by drug addiction – for which we send sick and poorly people to jail where they find easy access to more and nastier drugs.  This is the real madness that drugs cause.  It is the madness of deranged government ministers and their refusal to consider evidence or to resist pressure from their masters in Fleet Street.

What we need to do is say yes to a drugs policy that is designed to reduce harm and protect our communities.  Alcohol is promoted and so easily available as to be ridiculous, in every other shop on the high street, yet we control the access of children to alcohol and tobacco quite effectively.  But we abandon them to the street weed dealer who sells them muck grown by other children who have been trafficked from overseas and locked in hidden farms which are dangerous fire risks.  This is the shameful reality that our policies have produced.

Doctors freely prescribe anti-depressants, tranquilisers, highly toxic opioids such as tramadol, weird drugs for pain and epilepsy like gabapentin, which we don’t really understand at all.  Yet it is a criminal offence for a doctor to prescribe cannabis, a remedy that mankind has used safely and effectively for at least 10,000 years.

We mislead and misinform.  We encourage young people to go out and drink, yet we make ecstasy, MDMA, a drug far safer than even paracetamol, a class A substance , and we threaten people with years in jail just for handing a single dose to a friend.  It’s estimated that between two and ten million doses of MDMA are taken every weekend in the UK and we get about 50 deaths a year.  200 people die every year from paracetamol.  How much safer would MDMA be if the product was regulated with known strength and purity? It would probably be virtually harmless.

Now everyone is a victim of this drug war propaganda and the terrible effects of prohibition. Politicians, police officers, social workers, mothers and fathers have all been drenched in this propaganda from birth.  Many sincerely believe the rubbish they have been fed and they do all they can to pass on misguided ideas to the next generation.

We need to grow up, get a grip and drag Britain out of the dark ages. Drugs can cause harm but British drugs policy is a scourge on our society.  It damages the lives of millions and costs us billions.  Please oppose the motion, saying no to drugs is a nonsense.  Let’s say yes to a rational drugs policy.

Obituary. Peter Reynolds 1958 – 2016.

with one comment

peter-reynolds-composerIt only seems right that I record the passing of my namesake and compatriot, a man who made a huge impact on the world of music, not only in Wales but much further afield.

Just four months younger than me, he was born in Cardiff in January 1958, 10 miles from where I was born in Newport, the previous September.  We share the same three names: Peter John Reynolds. Clearly something of an eccentric but well respected, he is best known as the composer of the world’s shortest opera, ‘The Sands of Time’ (1993). It depicts a row that takes place during the boiling of an egg.

I can confirm that it is the only opera that I have listened to in full. Enjoy!

His obituary as published in The Times, 2nd November 2016

Peter Reynolds earned a place in Guinness World Records for The Sands of Time(1993), the world’s shortest opera. It lasts for three minutes, 34 seconds (no interval), about half the length of Darius Milhaud’s Deliverance of Theseus, which had held the record since 1928.

The piece is set in a suburban kitchen of the 1990s, as an egg is boiling (the length of the opera). Stan and Flo, husband and wife, are having an argument at breakfast when a knock at the door tells them that they have won the pools. Peace is restored as the egg is lifted out of the pan.

“It certainly has the influence of 19th-century Italian opera,” argued Reynolds, pointing out that his work included eight separate numbers. “Stan’s aria, ‘Down with the splash of cologne and deodorant spray’, was very much me doing early Verdi, the heroic tenor aria as in Il Trovatore. The patter song with its resonances of Gilbert and Sullivan is very quick.”

The Sands of Time, which has a libretto by Simon Rees, was conducted at its premiere at an outdoor shopping centre in Cardiff by Carlo Rizzi, the music director of Welsh National Opera. Reynolds later admitted that the work had been written in a hurry. “It took me an evening to write,” he said, adding: “I’m very proud to have used deodorant for the first time [in an opera]. It isn’t product placement. It’s simply facing reality in its harshest form.”

Later he would be embarrassed by the state of the work’s only copy. “I didn’t produce the neatest score in the world,” he said. “Twenty years on it’s still getting performances every year and each time I feel a bit more embarrassed about the old score.”

Peter John Reynolds was born in Cardiff in 1958. Almost as soon as he could walk he taught himself to play LPs and 78s on his parents’ 1954 radiogram. “I was enthusiastic, but none too careful and was often told off for playing 78s using an LP stylus,” he recalled.

He went to St Teilo’s school, studied music at University College, Cardiff, and was awarded a series of bursaries in the 1980s to attend composition classes at Dartington Summer School, with Morton Feldman, Peter Maxwell Davies and Gordon Crosse. In 1986 he was awarded the Michael Tippett award for composition, and the following year wrote his first large-scale commission, a work for chamber orchestra, that was performed at Dartington.

Over the following years Reynolds was an integral part of the vibrant Welsh music scene. He founded the PM Ensemble, major players in contemporary music at the end of the century; was artistic director of the Lower Machen Festival; wrote programme notes for more than 2,000 pieces of music; programmed concerts for St David’s Hall; set up a series of foyer concerts at Wales Millennium Centre; and, in 2009, published a history of the BBC National Orchestra of Wales.

In 1994 he joined the Royal Welsh College of Music and Drama, where he was friend, mentor and confidant to a wide range of students. He would caution them against wasting energy on large-scale composing, while encouraging vigorous discussion in the bar.

Reynolds’s music was characterised by stillness, simplicity, an occasional playfulness and a tendency to set unusual and quixotic texts. For example, Adieu to all Alluring Toys, a set of songs, took its title from the epitaph on an 18th-century child’s grave at a tiny country church in Breconshire. He was recently the recipient of a Creative Wales award, enabling him to explore the relationship between music, architecture and landscape.

He tended to compose in longhand rather than use computer software. “It slows me down and makes me consider more carefully what I write,” he said. “I remember that Morton Feldman used to say that copying out his music in different drafts brought him closer to the material.”

Friends recalled that he was often seen at his local farmers market, cooked a delicious tagine and enjoyed exploring cycle tracks around Cardiff on his bike. At the time of his death Reynolds, who never married, was working on a car-horn fanfare for the Vale of Glamorgan Festival, to be performed by vintage cars.
Peter Reynolds, composer, was born on January 12, 1958. He died suddenly on October 11, 2016, aged 58

 

Written by Peter Reynolds

November 27, 2016 at 8:56 am

Report Of Meeting With MHRA On Regulation of Cannabidiol (CBD).

with 11 comments

Tom Whettem, Cannabidol; Anthony Cohen, Elixinol UK; Tom Rowland, CBD Oils UK; Karl Spratt, Hempire; Peter Reynolds, CLEAR Cannabis Law Reform; Mike Harlington, GroGlo Research & Development

Tom Whettem, Canabidol; Anthony Cohen, Elixinol UK; Tom Rowland, CBD Oils UK; Karl Spratt, Hempire; Peter Reynolds, CLEAR Cannabis Law Reform; Mike Harlington, GroGlo Research & Development

Yesterday, 3rd November 2016, six delegates from the UK Cannabis Trade Association (UKCTA) met with Medicines and Health Products Regulatory Agency (MHRA) representatives at the agency’s headquarters in Victoria.

We were courteously received. The meeting was cordial, productive and enabled both sides to clarify their positions and better understand each other’s perspective.

In summary, in my opinion, there is no immediate threat to to CBD consumers or businesses. The MHRA has now extended until 31 December 2016 the date by which businesses should voluntarily comply with its opinion, either by withdrawing existing products from the market, or by complying with necessary regulation. Thereafter, the next step would be to begin the process of statutory enforcement.  This would take a matter of some months and I believe, even were this to be started, we are looking at more than a year before any impact would be felt.  More importantly, based on the meeting, I think the outcome is likely to be that we can negotiate a form of regulation that will work for everyone.

The MHRA team was led by Gerald Heddell, Director of Inspection, Enforcement and Standards. Also present were regulatory advisors David Olszowska and Chris Groutides; Dr Chris Jones, Manager of the Medicines Borderline Section; Greg Markey, Senior Medical Assessor and Malcolm Evans, Head of Patient, Public and Stakeholder Engagement.  Mr Heddell opened the meeting by thanking us for bringing to the agency’s attention just how many people are using CBD, some for quite serious medical conditions.

The MHRA set out its reasons for its opinion that products containing CBD used for medical purposes are medicines.  Greg Markey explained the mechanisms of action and pharmacology that had been considered and Dr Jones explained that the Borderline Section existed to deal specifically with products where it was difficult to determine whether they should be regarded as medicines or food supplements.  The example was offered of vitamin C where if it was being used to treat scurvy then it was clearly a medicine, whereas if it was used to supplement a normal diet it could be regarded as a food supplement.  We were able to explain that all so-called CBD products on the market, with the exception of crystals, are actually whole plant extracts from low-THC cannabis, usually industrial hemp.  We pointed out that the growth in the CBD market had been driven by people seeking the therapeutic benefits of medicinal cannabis which until now had been denied by the British government.

The nub of the issue is really the nature of the condition for which CBD is used.  The MHRA has already issued orphan designations for CBD for Dravet Syndrome, graft versus host disease and perinatal asphyxia.  Orphan designations are granted where the benefit of a medicine can be recognised even though necessary regulatory processes have not yet been completed.  It is important to understand that this is what has guided the MHRA’s opinion, viewing CBD as a medicine for very serious conditions.

We discussed a range of options whereby, at the lowest level, CBD products could continue to be marketed as a food supplement.  For minor conditions, not requiring medical supervision, it may be possible to obtain a Traditional Herbal Registration (THR) at a cost of a few hundred pounds.  A third option is a ‘Specials’ exemption where a doctor or prescriber has specified and taken responsibility for an unlicensed medicine for a particular patient.  Finally, the highest level is a Marketing Authorisation (MA) where the costs including fees and clinical trials are probably a minimum of £250,000.

It is our view that CBD products should be regulated at all these different levels dependent on the purpose for which they are used and the concentration at which CBD is present.  We have agreed that we will write formally setting out these proposals and the MHRA will respond accordingly.

The UKCTA and a number of individual companies have now obtained legal advice including counsel’s opinion.  We have shared this with the MHRA and formal solicitors letters have already been served.  In essence, the advice is that the MHRA has failed to comply with its own guidelines and requirements in issuing its opinion to CBD suppliers and that any requirement to comply with regulations would have to be addressed on an individual, product by product basis.

So, all in all, we believe the meeting was a success.  We demonstrated that the new trade association is to be taken seriously and that we will work constructively with the agency.  There was visible surprise at the level of professionalism we presented, particularly with the legal advice we had obtained.  I believe we convinced the MHRA that we could establish a set of rules, guidelines and standards that would enable the industry to comply with its requirements.

The CBD market in the UK is presently worth several million pounds a year.  If it is to continue to grow, provide safe, effective products for consumers and patients and job security for its workers, then we need to establish UKCTA so that it effectively represents the whole industry.  We need to show that we are responsible, we care, we are professionals and we are ready to put our collective head above the parapet as a legal, ethical and regulated industry.

UK Cannabis Trade Association Meeting With MHRA This Week.

leave a comment »

MHRA Headquarters

MHRA Headquarters

After all the speculation, many misleading and false reports and a plethora of attempts to interpret the MHRA’s actions concerning cannabidiol (CBD), this week the chips are down.

On Thursday 3rd November, at MHRA headquarters in Victoria, six representatives of the UK Cannabis Trade Association (UKCTA) will sit down with those responsible for the agency’s statements on CBD.  We will be armed with counsel’s opinion on the legality of the MHRA’s action but most importantly we hope to secure clarification for those who rely on CBD as a food supplement.  We will publish details of the outcome of the meeting as soon as we can.

Those attending as UKCTA representatives are:

Anthony Cohen, Elixinol UK
Mike Harlington, GroGlo Horticultural Research & Development
Peter Reynolds, CLEAR Cannabis Law Reform
Tom Rowland, CBD Oils UK
Karl Spratt, Hempire
Tom Whettem, Canabidol

The British Medical Journal (BMJ) Features The CLEAR Medicinal Cannabis Campaign.

with one comment

By Nigel Hawkes

By Nigel Hawkes

“Muddled thinking” over cannabis leaves patients in limbo, warn campaigners

BMJ 2016; 355 doi: http://dx.doi.org/10.1136/bmj.i5556 (Published 14 October 2016) Cite this as: BMJ 2016;355:i5556

Download PDF here

Companies selling cannabis based products have been told to remove them from the market within 28 days, after a review by the Medicines and Healthcare Products Regulatory Agency (MHRA) determined that they were medicinal products.

Campaigners for cannabis law reform welcomed the recognition that cannabidiol (CBD) had medicinal properties but warned that the MHRA’s action would deprive thousands of users of a product they relied on. They said that it was impossible to obtain marketing authorisation in the timescale given and may never be possible given the high costs of clinical trials and lack of patent protection for a product that contained many components.

“In the long term, it’s a good thing,” said Peter Reynolds of the pressure group CLEAR Cannabis Law Reform. “But my immediate concern is for the tens of thousands of people who use CBD and have become reliant on it. We urgently need interim measures so that supplies can continue.”

The MHRA sent letters on 3 October to 18 companies that sold CBD, saying that it had concluded that CBD met the definition of a medicinal product as defined in the Human Medicines Regulations as “any substance or combination of substances which may be used or administered to human beings either with a view to restoring, correcting, or modifying physiological functions by exerting a pharmacological, immunological, or metabolic action or to making a medical diagnosis.”

This meant, the letter said, that CBD products required a marketing authorisation before they could be sold. Marketing authorisation for drugs requires lengthy clinical trials, only justifiable if the product has patent protection. An alternative route is under the traditional herbal medicines regulations, but that requires evidence that the product has 30 years of use and applies only to minor conditions, where medical supervision is not required. Reynolds said that he thought it unlikely that CBD could qualify by this route.

Mike Barnes, a neurologist and former NHS consultant and chief executive, is clinical adviser to CLEAR. He said, “The decision by the MRHA to treat CBD products as medicines has also been done without thought to the consequences for many thousands of people in the UK who currently benefit from the products. It will have very significant, and in many cases terminal, impact on the many legitimate businesses that provide high quality products.

“The government must now act to sort out their muddled thinking and try to help those people with long term and often painful conditions who benefit from the ready and hitherto legal availability of natural cannabis products. It is ironic that in acknowledging the therapeutic benefits of CBD, the MRHA is effectively suspending access to a product that has enhanced the lives of thousands for many years.”

Crispin Blunt, an MP and CLEAR supporter, has written to the MHRA saying that the decision to designate CBD as a medicine is directly contradicted by the Home Office’s position that cannabis has no medicinal value.

“It is vital that we do not let this anomaly in government policy cause harm to people’s health,” his letter said. He asked for details of how the decision was reached, the consultations undertaken, which specific regulatory regime MHRA proposed for these products, and whether the continued supply of these products, regulated as food supplements, could be ensured until such time that medicinal marketing authorisations could be obtained.

The MHRA has not yet posted details on its website about the decision. In a statement it said that people who used CBD should speak to their GP or other healthcare professional. “We can provide regulatory guidance to any company who may wish to apply for a licence,” the statement added.